Search

everythinglearnresearchcommunity

for

Search:↓

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

A user shared a six-month update on hair improvement using Pyrilutamide and Minoxidil, noting significant hair regrowth and strength. Some participants questioned the legitimacy of the results and the source of Pyrilutamide.

Hair loss treatment with Pyrilutamide, Minoxidil, and Finasteride showed improvement after 4 months. Shedding reduced, hair feels stronger and healthier, with no side effects.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

Whey protein may slightly increase hair loss in men with androgenetic alopecia (AGA) due to elevated IGF-1 and testosterone levels, but the effect is minimal compared to treatments like finasteride and dutasteride. Many users argue that whey protein's impact on hair loss is negligible and that maintaining a healthy lifestyle is more important.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

Finasteride can cause dry eyes and vision issues due to its impact on the meibomian glands. Users have mixed experiences, with some experiencing eye discomfort and others having no side effects.

The user shared progress pictures showing significant hair regrowth from using finasteride, RU58841, and liquid minoxidil, emphasizing the importance of consistency. They noted that RU58841, a research chemical not FDA-approved, was effective when applied topically but warned of potential heart-related side effects.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

A 25-year-old man with hair loss from bleach damage is using oral minoxidil and considering adding Dutasteride for better regrowth and prevention. He seeks advice on Dutasteride's effectiveness and potential benefits over finasteride, and is also curious about RU58841.

Finasteride is the most effective treatment for reducing DHT and addressing hair loss compared to fish oil and saw palmetto. Topical treatments like RU58841 and minoxidil are also discussed, but finasteride remains the most effective option.

Hair loss may be linked to blood flow and inflammation, with treatments like Minoxidil, finasteride, and quercetin being discussed. The conversation also mentions the role of 5AR enzyme distribution in hair follicles.

Turmeric may slightly inhibit DHT, but it likely doesn't significantly impact hair loss. Creatine might increase DHT levels, but its effect on hair loss is debated and not conclusively proven.

Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.

Finasteride may affect male offspring's fertility and hormonal balance, with debates on whether to discontinue use before conception. Some users report no issues, while others highlight the high doses used in rat studies.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

Dutasteride is preferred over finasteride for hair loss due to fewer side effects. Combining dutasteride with minoxidil and RU58841 is effective for hair regrowth, even during steroid use.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The user is frustrated with the delayed delivery of their Pryiltamide order from Koshine. They mention the order was shipped on August 23 but have received no updates since.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.

A 25-year-old man discusses his struggles with his mother's opposition to his use of Finasteride for hair loss treatment, despite it improving his condition and self-control after a hair transplant. He expresses frustration over her blaming the medication for various issues and the stress caused by her insistence to stop taking it.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.

User experienced hair thickening with pyri but also side effects like reduced sex drive. Stopping pyri and returning to CB restored sex drive, suggesting pyri may go systemic or be incorrectly formulated.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.

Breezula protects hair follicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.